Please Wait.....
Report
Global Atypical Teratoid Rhabdoid Tumours Treatment Market Report and Forecast 2023-2031
Market Report I 2023-04-11 I 147 Pages I EMR Inc.
Global Atypical Teratoid Rhabdoid Tumours Treatment Market Report and Forecast 2023-2031
Global Atypical Teratoid Rhabdoid Tumours Treatment Market Outlook
The global atypical teratoid rhabdoid tumours (ATRT) treatment market is expected to grow at a compound annual growth rate (CAGR) of 7.9% from 2023 to 2031. The increasing incidence of ATRT, the development of novel treatments, and the growing demand for targeted therapies are the primary drivers of the market growth.
Atypical Teratoid Rhabdoid Tumours Treatment Market: Introduction
Atypical teratoid rhabdoid tumours (ATRT) are a rare and aggressive type of brain tumour that typically affects children under the age of three. The tumours are characterized by the loss of a tumour suppressor gene called INI1 or SMARCB1, which is responsible for regulating cell growth. ATRT is often difficult to treat and has a poor prognosis, with a five-year survival rate of less than 20%. The market is dominated by chemotherapy, which is the primary treatment for ATRT. The market is also driven by the development of targeted therapies and immunotherapies, which are designed to specifically target the tumour cells and enhance the immune response against cancer.
Atypical Teratoid Rhabdoid Tumours Epidemiology
ATRT is a rare type of cancer, accounting for less than 1% of all paediatric brain tumours. The incidence of ATRT is highest in children under the age of three, with approximately 60% of cases occurring in this age group. ATRT is more common in boys than girls, with a male-to-female ratio of approximately 1.5:1. The exact cause of ATRT is unknown but there are several risk factors that have been identified. These include genetic syndromes such as the rhabdoid tumour predisposition syndrome, exposure to ionizing radiation, and mutations in the INI1 or SMARCB1 gene.
ATRT is a highly aggressive tumour and has a poor prognosis. The five-year survival rate for children with ATRT is less than 20%. However, recent advances in treatment, including the development of targeted therapies and immunotherapies, have improved outcomes for some patients.
Atypical Teratoid Rhabdoid Tumours Treatment Market Segmentations
The market can be categorised into treatment method, route of administration, treatment channel, and region.
Market Breakup by Treatment Method
- Surgery
- Chemotherapy
- Radiation
- Targeted Immunotherapy
- Others
Market Breakup by Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
Market Breakup by Treatment Channel
- Public
- Private
Atypical Teratoid Rhabdoid Tumours Treatment Market Breakup by Region
- North America
? United States of America
? Canada
- Europe
? United Kingdom
? Germany
? France
? Italy
? Others
- Asia Pacific
? China
? Japan
? India
? ASEAN
? Australia
? Others
- Latin America
? Brazil
? Argentina
? Mexico
? Others
- Middle East and Africa
? Saudi Arabia
? United Arab Emirates
? Nigeria
? South Africa
? Others
Atypical Teratoid Rhabdoid Tumours Treatment Market Scenario
The market is expected to witness significant growth in the coming years, driven by the increasing incidence of ATRT and the development of novel treatments. The market is highly competitive, with several multinational companies and small and medium-sized enterprises operating in the market.
Chemotherapy is the primary treatment for ATRT and dominates the ATRT treatment market. However, the market is also driven by the development of targeted therapies and immunotherapies, which have shown promising results in clinical trials. The increasing demand for personalized medicine and the growing focus on precision oncology are expected to further drive market growth.
North America dominates the ATRT treatment market, accounting for over 50% of the global market share. The high incidence of ATRT in the region, coupled with the presence of a well-established healthcare infrastructure, is driving market growth. Europe is the second-largest market for ATRT treatment, with the increasing adoption of novel therapies and the growing focus on personalized medicine driving market growth.
The Asia Pacific region is expected to witness the highest growth rate during the forecast period, owing to the increasing incidence of ATRT in the region and the rising healthcare expenditure. The growing awareness about ATRT and the availability of new treatment options are also expected to contribute to market growth.
Key Players in the Global Atypical Teratoid Rhabdoid Tumours Treatment Market
The report gives an in-depth analysis of the key players involved in the atypical teratoid rhabdoid tumours treatment market, sponsors manufacturing the drugs, and putting them through trials to get FDA approvals. The companies included in the market are as follows:
- Takeda Pharmaceutical Company Limited
- Vyriad, Inc.
- Novartis AG
- Pfizer Inc.
- Ipsen Pharma
- Exelixis, Inc.
- Secura Bio
- Istari Oncology Inc.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage - Key Segmentation and Scope
2 Research Methodology
3 Executive Summary
4 Atypical Teratoid Rhabdoid Tumours Overview
4.1 Guidelines and Stages
4.2 Pathophysiology
4.3 Screening and Diagnosis
4.4 Treatment Pathway
5 Patient Profile
5.1 Patient Profile Overview
5.2 Patient Psychology and Emotional Impact Factors
5.3 Risk Assessment and Treatment Success Rate
6 Current Scenario Evaluation and Regulatory Framework
6.1 Emerging Therapies and Clinical Trials
6.2 Patent Landscape
6.2.1 Patent Overview
6.2.1.1 Patent Status and Expiry
6.2.1.2 Timelines from Drug Development to Commercial Launch
6.2.1.3 New Drug Application
6.2.1.3.1 Documentation and Approval Process
6.3 Cost of Treatment
6.4 Regulatory Framework
6.4.1 Regulatory Overview
6.4.1.1 US FDA
6.4.1.2 EU EMA
6.4.1.3 INDIA CDSCO
6.4.1.4 JAPAN PMDA
6.4.1.5 Others
7 Challenges and Unmet Needs
7.1 Treatment Pathway Challenges
7.2 Compliance and Drop-Out Analysis
7.3 Awareness and Prevention Gaps
8 Global Atypical Teratoid Rhabdoid Tumours Treatment Market
8.1 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Overview
8.2 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Analysis
8.2.1 Market Overview
8.2.1.1 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Historical Value (2016-2022)
8.2.1.2 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Forecast Value (2023-2031)
8.2.2 Global Atypical Teratoid Rhabdoid Tumours Treatment Market by Treatment Method
8.2.2.1 Market Overview
8.2.2.1.1 Surgery
8.2.2.1.2 Chemotherapy
8.2.2.1.3 Radiation
8.2.2.1.4 Targeted Immunotherapy
8.2.2.1.5 Others
8.2.3 Global Atypical Teratoid Rhabdoid Tumours Treatment Market by Route of Drug Administration
8.2.3.1 Market Overview
8.2.3.1.1 Oral
8.2.3.1.2 Parenteral
8.2.3.1.3 Intravitreal
8.2.3.1.4 Subretinal
8.2.3.1.5 Topical
8.2.3.1.6 Molecule Type
8.2.3.1.7 Others
8.2.4 Global Atypical Teratoid Rhabdoid Tumours Treatment Market by Distribution Channel
8.2.4.1 Market Overview
8.2.4.1.1 Hospital Pharmacies
8.2.4.1.2 Retail Pharmacies
8.2.4.1.3 Online Pharmacies
8.2.5 Global Atypical Teratoid Rhabdoid Tumours Treatment Market by Region
8.2.5.1 Market Overview
8.2.5.1.1 North America
8.2.5.1.2 Europe
8.2.5.1.3 Asia Pacific
8.2.5.1.4 Latin America
8.2.5.1.5 Middle East and Africa
9 North America Atypical Teratoid Rhabdoid Tumours Treatment Market
9.1 Market Share by Country
9.2 United States of America
9.2.1 Historical Trend (2016-2022)
9.2.2 Forecast Trend (2023-2031)
9.3 Canada
9.3.1 Historical Trend (2016-2022)
9.3.2 Forecast Trend (2023-2031)
10 Europe Atypical Teratoid Rhabdoid Tumours Treatment Market
10.1 Market Share by Country
10.2 United Kingdom
10.2.1 Historical Trend (2016-2022)
10.2.2 Forecast Trend (2023-2031)
10.3 Germany
10.3.1 Historical Trend (2016-2022)
10.3.2 Forecast Trend (2023-2031)
10.4 France
10.4.1 Historical Trend (2016-2022)
10.4.2 Forecast Trend (2023-2031)
10.5 Italy
10.5.1 Historical Trend (2016-2022)
10.5.2 Forecast Trend (2023-2031)
10.6 Others
11 Asia Pacific Atypical Teratoid Rhabdoid Tumours Treatment Market
11.1 Market Share by Country
11.2 China
11.2.1 Historical Trend (2016-2022)
11.2.2 Forecast Trend (2023-2031)
11.3 Japan
11.3.1 Historical Trend (2016-2022)
11.3.2 Forecast Trend (2023-2031)
11.4 India
11.4.1 Historical Trend (2016-2022)
11.4.2 Forecast Trend (2023-2031)
11.5 ASEAN
11.5.1 Historical Trend (2016-2022)
11.5.2 Forecast Trend (2023-2031)
11.6 Australia
11.6.1 Historical Trend (2016-2022)
11.6.2 Forecast Trend (2023-2031)
11.7 Others
12 Latin America Atypical Teratoid Rhabdoid Tumours Treatment Market
12.1 Market Share by Country
12.2 Brazil
12.2.1 Historical Trend (2016-2022)
12.2.2 Forecast Trend (2023-2031)
12.3 Argentina
12.3.1 Historical Trend (2016-2022)
12.3.2 Forecast Trend (2023-2031)
12.4 Mexico
12.4.1 Historical Trend (2016-2022)
12.4.2 Forecast Trend (2023-2031)
12.5 Others
13 Middle East and Africa Atypical Teratoid Rhabdoid Tumours Treatment Market
13.1 Market Share by Country
13.2 Saudi Arabia
13.2.1 Historical Trend (2016-2022)
13.2.2 Forecast Trend (2023-2031)
13.3 United Arab Emirates
13.3.1 Historical Trend (2016-2022)
13.3.2 Forecast Trend (2023-2031)
13.4 Nigeria
13.4.1 Historical Trend (2016-2022)
13.4.2 Forecast Trend (2023-2031)
13.5 South Africa
13.5.1 Historical Trend (2016-2022)
13.5.2 Forecast Trend (2023-2031)
13.6 Others
14 Global Atypical Teratoid Rhabdoid Tumours Treatment Market Dynamics
14.1 Market Drivers and Constraints
14.2 SWOT Analysis
14.3 Porter's Five Forces Model
14.4 Key Demand Indicators
14.5 Key Price Indicators
14.6 Industry Events, Initiatives, and Trends
14.7 Value Chain Analysis
15 Supplier Landscape
15.1 Takeda Pharmaceutical Company Limited
15.1.1 Company Overview
15.1.2 Product Portfolio
15.1.3 Demographic Reach and Achievements
15.1.4 Mergers and Acquisitions
15.1.5 Certifications
15.2 Vyriad, Inc.
15.2.1 Company Overview
15.2.2 Product Portfolio
15.2.3 Demographic Reach and Achievements
15.2.4 Mergers and Acquisitions
15.2.5 Certifications
15.3 Novartis AG
15.3.1 Company Overview
15.3.2 Product Portfolio
15.3.3 Demographic Reach and Achievements
15.3.4 Mergers and Acquisitions
15.3.5 Certifications
15.4 Pfizer Inc.
15.4.1 Company Overview
15.4.2 Product Portfolio
15.4.3 Demographic Reach and Achievements
15.4.4 Mergers and Acquisitions
15.4.5 Certifications
15.5 Ipsen Pharma
15.5.1 Company Overview
15.5.2 Product Portfolio
15.5.3 Demographic Reach and Achievements
15.5.4 Mergers and Acquisitions
15.5.5 Certifications
15.6 Exelixis, Inc.
15.6.1 Company Overview
15.6.2 Product Portfolio
15.6.3 Demographic Reach and Achievements
15.6.4 Mergers and Acquisitions
15.6.5 Certifications
15.7 Secura Bio
15.7.1 Company Overview
15.7.2 Product Portfolio
15.7.3 Demographic Reach and Achievements
15.7.4 Mergers and Acquisitions
15.7.5 Certifications
15.8 Istari Oncology Inc.
15.8.1 Company Overview
15.8.2 Product Portfolio
15.8.3 Demographic Reach and Achievements
15.8.4 Mergers and Acquisitions
15.8.5 Certifications
16 Global Atypical Teratoid Rhabdoid Tumours Treatment Market- Drug Distribution Model (Additional Insight)
16.1 Overview
16.2 Potential Distributors
16.3 Key Parameters for Distribution Partner Assessment
17 Payment Methods (Additional Insight)
17.1 Government Funded
17.2 Private Insurance
17.3 Out-of-Pocket
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security